A Phase II, Randomised, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Efficacy of 28 Day Oral Administration of AZD9668 in Patients With Bronchiectasis

Trial Profile

A Phase II, Randomised, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Efficacy of 28 Day Oral Administration of AZD9668 in Patients With Bronchiectasis

Completed
Phase of Trial: Phase II

Latest Information Update: 20 Feb 2013

At a glance

  • Drugs AZD 9668 (Primary)
  • Indications Bronchiectasis
  • Focus Pharmacogenomic; Therapeutic Use
  • Acronyms NEPAL
  • Most Recent Events

    • 24 Jul 2012 Additional primary endpoints identified as reported by ClinicalTrials.gov.
    • 24 May 2012 Planned number of patients changed from 40 to 60 as reported by European Clinical Trials Database.
    • 24 May 2012 Additional trial location (Denmark) added as reported by European Clinical Trials Database.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top